Inhibition of L-selectin and P-selectin mediated binding using heparin
AssigneeThe Regents of the University of California
InventorsAjit Varki, Andrea Koenig
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of inhibiting L-selectin and P-selectin mediated binding in a subject by administering heparin to the subject in an amount that does not produce substantial anticoagulant activity or undesirable bleeding in the subject. In addition, the invention provides methods of treating a subject having a pathology characterized, at least in part, by abnormal L-selectin or P-selectin mediated binding by administering heparin to the subject in an amount that results in attaining a concentration of less than about 0.2-0.4 units heparin per ml of plasma in the subject.
Claims19
A method of selectively inhibiting selectin mediated binding in a subject by administering an amount of heparin that does not produce substantial anticoagulant activity or undesirable bleeding.
A method of inhibiting L-selectin mediated binding in a subject by administering an amount of heparin that does not produce substantial anticoagulant activity or undesirable bleeding.
A method of inhibiting P-selectin mediated binding in a subject by administering an amount of heparin that does not produce substantial anticoagulant activity or undesirable bleeding.
A method of treating L-selectin and P-selectin related pathology by administering an amount of heparin that does not produce substantial anticoagulant activity or undesirable bleeding.
A method of treating P-selectin related pathology by administering an amount of heparin that does not produce substantial anticoagulant activity or undesirable bleeding.
Dependencies are inferred from the claim text.